Clients

CSR Study : Crunch could reduce corporate social responsibility

In a poll by Echo Research , 36 per cent of senior professionals said they believed the number of corporate social responsibility programmes would fall ...

Novartis Study

Omnibus Survey, Echo Research, April-May 2008. [2] Ezzati et al. Selected major risk factors and global regional burden of disease. The Lancet. ...

Jolly Good Fellows with a Purpose

by David Michaelson, Echo Research.

Secteur d'activité	Entreprises
Industrie pharmaceutique	AstraZeneca, Aventis, Baxter Healthcare, Cephalon, Ely Lilly, GlaxoSmithKline, Hoffman La Roche, Janssen, Johnson & Johnson, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Parke Davis, Pfizer, Rhône-Poulenc, Roche
Agences gouvernementales, ONG et autres associations	BioIndustries Association, British Medical Association, BUPA, Department of Health, Global Alliance for Vaccines & Immunization (GAVI), Health Education Authority (HEA), Health Education Board for Scotland (HEBS), Health & Safety Executive, Interscience, National Health Service (NHS), National Pharmaceutical Association, Organisation des Nations Unies pour l'alimentation et l'agriculture (FAO), PPP
Organisations caritatives	British Heart Foundation, Croix rouge britannique, Imperial Cancer Research Fund, International Committee of the Red Cross, UNAIDS, UNICEF

CSR Study : Crunch could reduce corporate social responsibility

Novartis Study

Jolly Good Fellows with a Purpose

Secteur d'activité

Entreprises

Clients